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Imported malaria has been an increasing problem in
several Western countries in the last 2 decades. To calcu-
late the risk factors of age, sex, and travel destination in
Swedish travelers, we used data from the routine reporting
system for malaria (mixture of patients with and without
adequate prophylaxis), a database on travel patterns, and
in-flight or visa data on Swedish travelers of 1997 to 2003.
The crude risk for travelers varied from 1 per 100,000 trav-
elers to Central America and the Caribbean to 357 per
100,000 in central Africa. Travelers to East Africa had the
highest adjusted odds ratio (OR = 341, 95% confidence
intervals [CI] 134–886) for being reported with malaria,
closely followed by travelers to central Africa and West
Africa. Male travelers as well as children <1–6 years of age
had a higher risk of being reported with malaria (OR = 1.7,
95% CI 1.3–2.3 and OR = 4.8, 95% CI 1.5–14.8) than
women and other age groups. 
I
mported malaria has been an increasing problem in
Sweden and other Western countries in the last 2
decades. Two possible reasons for this increase are the
increase in the number of travelers to tropical countries, as
well as a growing number of immigrants from malaria-
endemic countries (1–3). Even though the number of
malaria cases has been declining during the past years in
Sweden (4), the risk for travelers is still evident and should
be a concern for physicians who give pretravel advice or
evaluate a returning traveler with fever. 
Several studies have assessed malaria risk in travelers
to specific countries (5–8). The risk of a traveler’s acquir-
ing malaria has been considered highest in sub-Saharan
Africa and Papua New Guinea, intermediate on the Indian
subcontinent, and low in Southeast Asia and Latin
America. The numbers assigned to the relative risk in these
regions, however, are quite variable (9–12). The total num-
ber of travelers is often unknown, and most reports based
on national reporting data therefore lack a denominator
(2,9). Hence, making a risk assessment on the basis of such
figures is difficult. Other approaches to achieve risk esti-
mates are case-control studies. In 1 such Danish study, the
country-specific risk for acquiring malaria varied from 714
per 100,000 travelers to Ghana to 2.5 per 100,000 to
Thailand (13). 
To our knowledge, no previous study based on national
data over an extended period has related the number of
cases of malaria diagnosed in returning travelers from
malaria-endemic areas to continuously collected data on
the total number of travelers to that same area. Through
access to one of Europe’s largest ongoing surveys on trav-
el patterns (14) and to data on reported malaria, we ana-
lyzed the risk factors for malaria in returning Swedish
travelers from 1997 to 2003. 
Materials and Methods
Cases and Controls
Cases were derived from the routine Swedish reporting
system. Malaria is a reportable disease in Sweden, and all
patients in whom the disease is diagnosed are reported
from both the clinician treating the patient and the micro-
biology laboratory confirming the diagnosis. By using a
unique personal identification number, issued to all
Swedish residents, the 2 reporting sources can be linked.
Thus, all cases reported from 1997 to 2003 were included.
Since routine surveillance data were not sufficiently
detailed regarding information on prophylaxis, the patients
included a mixture of those with and without adequate pro-
phylaxis. To assess travel risk specifically, newly arrived
immigrants and refugees, who lack a personal identifica-
tion number, were excluded from the study. 
Controls were obtained from the Swedish Travel and
Tourist Database, a commercial ongoing survey, based on
a randomized selection of 2,000 members of the Swedish
population each month (14). These persons are inter-
viewed by telephone in regard to all overnight travel (busi-
ness as well as pleasure) in the preceding month, and the
data are weighted and extrapolated to estimate the total
numbers of Swedish travelers. When the number of
respondents has been too low to give a reliable estimate of
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(rather than single countries) are given in this database.
This practice was used for all malaria-endemic countries in
this report, except for Thailand, where country-specific
data were available for the period 2001–2003.
Out of the total database, which contained detailed
information from almost 170,000 interviews, information
about all respondents who had traveled to malaria-endem-
ic areas from 1997 to 2003 was extracted. To evaluate data
quality in the travel database, the weighted and extrapolat-
ed estimates of total numbers of travelers to Thailand,
India, The Gambia, and South Africa were compared with
in-flight or visa data on Swedish travelers. These figures
were obtained by courtesy of the embassies of the respec-
tive country in Sweden, except for The Gambia, where the
figures were supplied by the Central Statistics Department
of the Gambia, (through the courtesy of the Swedish
embassy in Dakar, Senegal). For each study participant
(patients and controls), we used the following information:
age, sex, year and month of infection (patients); year and
month of travel (controls); country of infection (patients);
and country/region of travel (controls). No data on any ill-
ness were available for controls. The latest available infor-
mation on annual malaria incidence among the local
population in the studied countries and regions was
accessed from the World Health Organization (WHO)
(15).
Statistics
The risk for disease per 100,000 travelers, with 95%
confidence intervals (95% CI), was calculated by using
reporting data as numerator and the estimated total numbers
of travelers from the travel database as denominator. For
the 4 specific countries mentioned above, the risk per
100,000 travelers was also calculated by using in-flight and
visa data as denominator. Since malaria is a rare disease in
Sweden and controls were chosen randomly from the entire
Swedish population, we could use odds ratios (OR) with
corresponding 95% CI as relative risk estimates to assess
the association between risk factors (age, sex, and travel
destination) and outcome (being reported with malaria). 
Each risk factor was first analyzed in a univariate
model. To adjust for confounding, we then used a multi-
variate logistic regression model with these variables, and
we also included month of travel or infection. The param-
eter with the lowest OR in each category was used as ref-
erence in the models. Likelihood ratio statistics were used
to assess whether each variable in the model contributed
significantly to the model and to test for interaction. All
analyses were performed with Stata 6.0 software (Stata
Corporation, College Station, TX, USA).
The travel database contains aggregated data only.
Reportable data are regulated by the Communicable
Disease Act and contain full personal identification. The
subset of the reporting database abstracted for this study
did not contain any information that could be linked to a
specific person. The study was approved by the Ethics
Committee of the Karolinska Institute, Stockholm,
Sweden.
Results
From 1997 to 2003, a total of 975 persons were report-
ed with malaria in Sweden; 118 of them were newly
arrived immigrants or refugees and thus excluded from
further analysis (Table 1). Of the remaining 857 persons,
348 were infected with Plasmodium falciparum, 178 with
P. vivax, 47 with P. ovale, and 15 with P. malariae (Tables
2 and 3). In 269 patients, the report did not contain data on
Plasmodium species. Most of these patients were seen in
1997 before the full implementation of a new reporting
system that year. Little variation occurred, either in the
number of reported cases or the species distribution over
the period, except in the last year studied (2003), which
had <65% of the mean of reported cases for the preceding
years. This low figure in 2003 was mainly due to a
decreased number of reported P. falciparum cases. 
A total of 16,255 persons with overnight travel abroad
were recorded in the travel database for the period
1997–2003. Of these, 881 (projected to a total of 3.5 mil-
lion travelers) had traveled to malaria-endemic countries
or regions, as defined by WHO (16) and were included as
controls (Tables 3 and 4). Of the travel destinations, east
Asia (mainly Thailand) was dominant.
Three quarters of all cases and 93% of the P. falciparum
cases were seen in travelers from sub-Saharan Africa
(Table 4). The crude risk for travelers to different regions
varied from 1 per 100,000 travelers to Central America and
the Caribbean to 357 per 100,000 in central Africa. In the
multivariable analysis, OR for being diagnosed with any
malaria species after return to Sweden was calculated for
various risk factors (Table 1). Compared to the reference
region (Central America and the Caribbean), travelers to
East Africa had the highest OR for being reported with
malaria, closely followed by travelers to central Africa and
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same “middle” range as southern Africa. Southeast Asia
and South America had similar ORs, at the lower range.
The malaria risk in Arab countries did not differ signifi-
cantly from the risk in Central America and the Caribbean. 
Malaria was significantly more often diagnosed in men
than in women, as well as in the age-group <1–6 years,
after adjustments were made for the various confounders.
The calculated malaria risk per 100,000 travelers in 4
countries with alternative sources of travel information is
shown in Table 5, with risk data based on the travel data-
base, and the annual malaria incidence reported to WHO
(15) as comparisons. 
Discussion
These results are based on official reports of malaria,
with data from one of the largest ongoing population-based
surveys on travel patterns in Europe as denominator. The
laboratory method of microscopy of a blood film for
malaria is well defined, and the reporting of diagnosed
malaria is believed to be relatively complete in Sweden.
Since case-patients are reported both by the clinician and
the laboratory, the overall sensitivity of the Swedish sur-
veillance system is comparatively high, with >95% of
diagnosed diseases being reported (17). 
The information in the tourist and travel database and
the reporting database were not fully consistent. The trav-
el database did not contain any data on travel-related ill-
nesses, while the official reports did not contain
information on length of stay. Previous studies have shown
that the duration of stay influences the risk for malaria
(5,12,13), but this factor could not be evaluated in this
study. Because the tourist and travel database classification
sometimes included both malaria-endemic and malaria-
nonendemic countries within the same region, some trav-
elers who only visited regions that were not
malaria-endemic were included in the denominator for the
region. Therefore, the risk for the region may be underes-
timated, e.g., in east Asia, which includes several malaria-
free countries. However, many of these countries are
comparatively rare as tourist destinations. 
To further evaluate the precision of the estimates from
the tourist database, we also used official in-flight and visa
data obtained from 4 countries. Risk estimates from the 2
sources for Thailand and The Gambia/West Africa had
good agreement. For India and the Indian Subcontinent
and South Africa/southern Africa, where we did not have
any tourist data per country, most travelers were going to
India and South Africa, respectively, while most malaria
patients were from other countries in these regions. The
risk estimates from the 2 sources were therefore in less
agreement with each other in these regions.
We found that men had a significantly higher risk of
being reported with malaria compared to women. A pre-
dominance of imported malaria infections in male patients
has been documented before (2,5,18,19); men are often
also less compliant with chemoprophylaxis than women
(5). We also found that children <6 years of age had a sig-
nificantly higher risk of being reported with malaria. To
our knowledge, this risk has not been described before.
Many of these young children belonged to immigrant fam-
ilies with roots in the country of infection, where they vis-
ited friends and relatives; such children are referred to as
“VFRs” (20,21). Parents may be unaware of the fact that
the children lack the immunity against malaria when
returning “home.” 
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Migration Board, >775,000 persons were granted perma-
nent residence permit in Sweden during the period
1980–2002. Alarge proportion of these persons came from
countries where malaria is highly endemic. Asurvey based
on Norwegian surveillance data has shown that the inci-
dence of malaria was higher in VFRs than in people of
Norwegian origin (22). In our study, distinguishing native
Swedes from persons with an origin in other countries was
not possible among controls. However, reporting data,
which often includes this information, indicated that a
large number of the patients were VFRs who had visited
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Ethiopia, Uganda, Bangladesh, and Pakistan. Our data thus
suggest that VFRs are a risk group requiring special atten-
tion. These persons may be less inclined than other travel-
ers to get pretravel advice and to use chemoprophylaxis
against malaria (21,23). 
P. falciparum malaria is the prime target for chemopro-
phylaxis to prevent death and severe disease. Although we
considered doing a separate risk analysis for this species,
reporting at the species level in the first year of the study
was not sufficiently complete to allow for meaningful
analysis. Furthermore, other malaria species also con-
tribute substantially to malaria illness in travelers (24).
Falciparum malaria is a clinically overt disease and will
most probably be diagnosed. For other malaria species, a
few cases, especially in persons with partial immunity,
might be missed, thus underestimating the true risk. 
No systematically collected data on chemoprophylaxis
are included in this study, an obvious limitation when
assessing the malaria risk. However, previously published
reporting data from 2003 for P. falciparum infection indi-
cate that 12 of 17 Swedish travelers had not taken any pro-
phylaxis, and another 2 had taken drugs with insufficient
effect for the country they visited. Of 34 VFRs, only a few
had taken prophylaxis (25). Prophylaxis influences the
number of cases, as do other factors associated with the
behavior of individual travelers, such as use of mosquito-
protective measures and the standard of housing visited, on
which we do not have any information from reports.
Furthermore, local malaria transmission intensity is key to
the malaria risk for a traveler. Within several malaria-
endemic countries, the risk for malaria varies greatly,
reflecting local transmission intensity at the district level
(16,26,27). This local variation, together with the different
travel patterns within countries, may greatly influence the
risk of travelers contracting malaria. For example, in
Thailand, most Swedish travelers go to areas of the country
in which no malaria occurs, a fact that could partly explain
the low incidence in Swedish travelers compared to WHO
data on local incidence. This low incidence in Swedish
travelers is in line with a previously cited report on malaria
risk in Danish residents traveling to Thailand (13), where
the risk was estimated to be 2.5 per 100,000 travelers. Our
corresponding figure, with denominator data from the
embassy, was 2.1 per 100,000. A British study reported a
slightly higher risk, 8.2 per 100,000 (6). All 7 Swedish trav-
elers who contracted P. falciparum malaria in Thailand
from 1997 to 2003 had visited regions outside of the usual
charter tourist destinations, such as remote national parks
and jungle areas. Another example is The Gambia, where
the average Swedish tourist often stays most (or all) of the
vacation in beach resorts by the coast, where the malaria
transmission intensity is lower than in inland areas (28). 
Discrepancies do exist between the calculated risks for
Swedish travelers to have malaria diagnosed in Sweden
after traveling to malaria-endemic regions, and the inci-
dence rates of patients in the same regions reported to
WHO. Several factors could explain these differences,
including the small number of Swedish malaria cases, the
fact that indigenous malaria is associated with more than
just transmission intensity, i.e., poverty (29), duration of
exposure, and different sensitivity of the surveillance and
reporting systems in different countries. Data from Africa,
especially, are incomplete (29). 
In general, the order of magnitude of the relative risk
for malaria in the different regions was consistent with ear-
lier data on relative malaria risk for travelers (9–12). Based
on these risk data, we divided the regions into 3 groups:
sub-Saharan Africa (except for southern Africa) exhibited
the greatest relative risk for malaria in returning travelers
(>250), followed by India and southern Africa (relative
risk [RR] ≈50) and at the lower end Southeast Asia, South
America, and the Arab countries (RR <10). A number of
other studies have shown higher risk for acquiring malaria
in West Africa compared to East Africa (5,8). Our data
show higher risk in those visiting central Africa and West
Africa than East Africa, corresponding to these previous
studies. Our results are representative for the overall
malaria risk in Swedish travelers and are also likely to
reflect the risk in travelers from other European countries. 
This study confirms that the risk of a traveler’s con-
tracting malaria is highest in Africa, south of the Sahara,
and that male travelers and small children constitute
groups with increased risks. Furthermore the added com-
plexity of immigrants from malaria-endemic areas needs
to be considered when discussing malaria prevention
among travelers. All pretravel advice needs to be individu-
alized for each traveler, based on the exact travel route,
season, and type of travel.
Dr. Askling is a resident physician at the Swedish Institute
for Infectious Disease Control, with a special interest in interna-
tional health, travel medicine, and infectious diseases epidemiol-
ogy. 
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